Why the study?
Does SSRI use during pregnancy increase the risk of fetal cardiac defects and newborn persistent pulmonary hypertension?
Does SSRI use during pregnancy increase the risk of fetal cardiac defects and newborn persistent pulmonary hypertension?
The ACOG recommends individualizing SSRI/SNRI treatment during pregnancy and avoiding paroxetine when possible due to risks of fetal cardiac defects and newborn persistent pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May influence SSRI/SNRI selection to minimize fetal risks in pregnancy; extends prior associations into Level 1 guidance.
Depression is a common condition among women of reproductive age, and selective serotonin reuptake inhibitors (SSRIs) are frequently used for the treatment of depression. However, recent reports regarding SSRI use during pregnancy have raised concerns about fetal cardiac defects, newborn persistent pulmonary hypertension, and other negative effects. The potential risks associated with SSRI use throughout pregnancy must be considered in the context of the risk of relapse of depression if maintenance treatment is discontinued. The American College of Obstetricians and Gynecologists' Committee on Obstetric Practice recommends that treatment with all SSRIs or selective norepinephrine reuptake inhibitors or both during pregnancy be individualized and paroxetine use among pregnant women or women planning to become pregnant be avoided, if possible.
No takes yet. Share an insight, caveat, or question.
A 2006 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: